NCT00891657

Brief Summary

This study is planned as a prospective, randomised, parallel, controlled, multi-centre, open label, comparative evaluation of SprayShield™ Adhesion Barrier plus good surgical technique, versus good surgical technique alone, with a blinded, third party video evaluation of adhesion formation at second look laparoscopy (SLL) following laparoscopic myomectomy.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
15

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Nov 2008

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2008

Completed
6 months until next milestone

First Submitted

Initial submission to the registry

April 30, 2009

Completed
1 day until next milestone

First Posted

Study publicly available on registry

May 1, 2009

Completed
Same day until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2009

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2009

Completed
1.3 years until next milestone

Results Posted

Study results publicly available

August 31, 2010

Completed
Last Updated

September 7, 2017

Status Verified

August 1, 2017

Enrollment Period

6 months

First QC Date

April 30, 2009

Results QC Date

July 13, 2010

Last Update Submit

August 7, 2017

Conditions

Keywords

AdhesionFibroidMyomaLeiomyomaMyomectomy

Outcome Measures

Primary Outcomes (4)

  • Number of Sites Adherent to the Uterus

    The number of times an adhesion is attached to the uterus.

    8-12 weeks post myomectomy

  • Mean Severity Score of Sites Adherent to the Uterus

    The scoring for severity is as follows: 0=no adhesions, 1=filmy, avascular adhesions, 2=vascular and/or dense adhesions, and 3=cohesive adhesions.

    8-12 weeks post myomectomy

  • Mean Extent Score of Sites Adherent to the Uterus

    0 =no adhesions, 1=covering \<25% of locations' total area, 2=covering 26% to 50% of locations' total area, and 3=covering \>51% of locations' total area.

    8-12 weeks post myomectomy

  • Area of Sites Adherent to the Uterus (cm^2)

    8-12 weeks post myomectomy

Study Arms (2)

SprayShield™

EXPERIMENTAL

SprayShield™

Device: SprayShield™

Control

NO INTERVENTION

No adhesion barrier administered.

Interventions

Anti-adhesion barrier

SprayShield™

Eligibility Criteria

Age18 Years+
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Females, 18 years of age or older, of child-bearing potential.
  • Subject has at least one myoma \>= 3 cm.

You may not qualify if:

  • Pregnant or lactating females.
  • Females undergoing prior open or closed myomectomy for treatment of myomas.
  • Evidence of current active endometriosis or infection
  • History of or active inflammatory bowel disease or pelvic inflammatory disease.
  • Presence of a frozen pelvis, or hydrosalpinges.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Pius Clinic

Oldenburg, Germany

Location

MeSH Terms

Conditions

LeiomyomaMyomaTissue Adhesions

Condition Hierarchy (Ancestors)

Neoplasms, Muscle TissueNeoplasms, Connective and Soft TissueNeoplasms by Histologic TypeNeoplasmsCicatrixFibrosisPathologic ProcessesPathological Conditions, Signs and Symptoms

Limitations and Caveats

The very small sample size makes it difficult to detect any real differences between the treatments, if such differences exist.

Results Point of Contact

Title
Director, Medical Affairs
Organization
Integra LifeSciences

Study Officials

  • Rudy Leon De Wilde, MD

    Pius Clinic

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 30, 2009

First Posted

May 1, 2009

Study Start

November 1, 2008

Primary Completion

May 1, 2009

Study Completion

May 1, 2009

Last Updated

September 7, 2017

Results First Posted

August 31, 2010

Record last verified: 2017-08

Locations